Teva Purinethol (correction)
Executive Summary
Purinethol (6-mercaptopurine) is a Teva product; it was misidentified as a GlaxoSmithKline product in a recent story in "The Pink Sheet" (Oct. 30, p. 33). Teva received rights to Purinethol July 1 as part of its patent settlement with GSK regarding Relafen (nabumetone) generics (1"The Pink Sheet" May 5, 2003, In Brief)...
You may also be interested in...
Teva/GSK settle Relafen litigation
All patent litigation between Teva and GSK regarding generics of Relafen (nabumetone) has been settled, Teva says April 30. Teva entered generic nabumetone market in August 2001 with 500 mg and 750 mg tablets following successful Boston federal court challenge of GSK patent (1"The Pink Sheet" Aug. 20, 2001, p. 14)...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.